The latest data point for CVS's diluted EPS in Q4'25 stands at 2.32 USD, marking a significant recovery from the sharp decline to -3.13 USD in Q3'25 and representing the highest value in the observed period from Q1'23 to Q4'25. Over the timeframe from Q1'23 to Q4'25, CVS's diluted EPS exhibited high volatility with an overall fluctuating trend, starting at 1.65 USD in Q1'23, peaking at 1.75 USD in Q3'23, and experiencing notable drops to 0.88 USD in Q1'24 and a drastic low of -3.13 USD in Q3'25 before rebounding to 2.32 USD. Year-over-year EPS growth mirrored this instability, with extreme swings including a -96% plunge in Q3'24 and a staggering -4,571% decline in Q3'25, contrasted by strong positive growth of 167% in Q3'23 and 77% in Q4'25, underscoring periods of operational challenges and subsequent improvements in profitability.